在骨髓瘤化学抵抗中,有 circRNA, lncRNA 和 miRNA 的竞争性内源网络
Shuang Qin1, Yuting Wang1, Chunhui Ma2
1Department of Medical Imaging, Tongji Hospital, Tongji University School of Medicine, Xincun Road No. 389, Shanghai, 200065, China.
European journal of medical research
|September 16, 2023
概括
骨髓瘤的化疗耐药性是一个主要的挑战. 本综述探讨了包括圆形和长非编码RNA在内的非编码RNA如何形成在这种骨癌中驱动药物耐药性的网络.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 骨髓瘤仍然是一个致命的骨瘤,尽管治疗进展,但生存率停滞不前.
- 多种药物耐药性显著阻碍了骨髓瘤患者的有效化疗.
- 非编码RNAs (ncRNAs) 越来越多地被认为是它们在基因表达和癌症等病理条件中的调节作用.
研究的目的:
- 审查骨髓瘤中化疗耐药性的分子机制.
- 阐明竞争的内源RNA (ceRNA) 网络,包括循环RNA (circRNAs),长非编码RNA (lncRNAs) 和微RNA (miRNAs) 在骨髓瘤药物耐药性的作用.
- 突出潜在的干预目标,以改善患者的治疗结果.
主要方法:
- 文献综述侧重于circRNA-, lncRNA-和miRNA介导的ceRNA网络.
- 对调查骨髓瘤药物耐药性机制的研究进行分析.
- 对癌症化学疗法耐药性中ncRNA调节的当前理解的综合.
主要成果:
- 环RNA和lncRNA通过与miRNA位点结合,充当竞争的内源RNA.
- 这些相互作用调节信使RNA (mRNA) 的表达,影响癌症的发病,进展和耐药性.
- lncRNA/circRNA-miRNA-mRNA ceRNA网络与骨髓瘤中化疗耐药性的发展有关.
结论:
- 了解复杂的ncRNA介导的ceRNA网络对于破译骨髓瘤药物耐药性至关重要.
- 阐明这些分子机制可以确定新的治疗点,以克服化疗耐药性.
- 对这些网络的进一步研究对改善骨髓瘤治疗疗效和患者存活率具有重大前景.
相关概念视频
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K